Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Eur J Surg Oncol ; 49(11): 107080, 2023 11.
Artigo em Inglês | MEDLINE | ID: mdl-37738873

RESUMO

INTRODUCTION: Outcomes of major surgeries in tertiary educational hospitals have been complicated by the referral of high-risk patients and the participation of trainees in surgical procedures. We analyzed outcomes of major hepatectomies in a tertiary academic setting emphasizing the role of training and obesity on textbook outcomes (TO). MATERIALS AND METHODS: 971 adult patients who underwent open major hepatectomy (Mesohepatectomy [n = 111], hemihepatectomy [n = 610], and extended hepatectomy [n = 250]) were evaluated. A TO was defined as: a negative resection margin, no grade B/C bile leak, no major complications, no in-hospital mortality, and no 30-day readmission. TOs were compared following operations performed by senior surgeons and those performed by junior surgeons under the supervision of senior surgeons and between patients with and without obesity. RESULTS: TO was achieved in 70.1% of patients overall (78.4% in mesohepatectomy, 73.1% in hemihepatectomy, and 59.2% in extended hepatectomy). The rate of TO was similar following operations performed by and supervised by a senior surgeon (69.3% vs 71.0%, p = 0.570). The rate of TO was significantly lower in patients with obesity (41.5% vs 74.6%, p < 0.001). Factors including increased age (odds ratio [OR] for 10-year increase = 0.83, 95% confidence interval [CI]: 0.73-0.96, p = 0.009), obesity (OR = 0.25, 95%CI: 0.16-0.37, p < 0.001), biliodigestive anastomosis (OR = 0.27, 95%CI: 0.19-0.40, p < 0.001), and portal vein resection (OR = 0.49, 95%CI: 0.28-0.87, p = 0.014) lower the rate of TO. CONCLUSION: Promising outcomes are possible after major hepatectomy in an academic setting. Obese patients and those undergoing more complex surgeries had a higher risk of poor postoperative outcomes.


Assuntos
Neoplasias Hepáticas , Fígado , Adulto , Humanos , Hepatectomia/métodos , Obesidade/complicações , Obesidade/epidemiologia , Veia Porta , Encaminhamento e Consulta , Estudos Retrospectivos , Complicações Pós-Operatórias/etiologia , Neoplasias Hepáticas/cirurgia , Resultado do Tratamento
2.
Sci Rep ; 11(1): 3095, 2021 02 04.
Artigo em Inglês | MEDLINE | ID: mdl-33542274

RESUMO

Prophylactic drainage after major liver resection remains controversial. This systematic review and meta-analysis evaluate the value of prophylactic drainage after major liver resection. PubMed, Web of Science, and Cochrane Central were searched. Postoperative bile leak, bleeding, interventional drainage, wound infection, total complications, and length of hospital stay were the outcomes of interest. Dichotomous outcomes were presented as odds ratios (OR) and for continuous outcomes, weighted mean differences (MDs) were computed by the inverse variance method. Summary effect measures are presented together with their corresponding 95% confidence intervals (CI). The certainty of evidence was evaluated using the Grades of Research, Assessment, Development and Evaluation (GRADE) approach, which was mostly moderate for evaluated outcomes. Three randomized controlled trials and five non-randomized trials including 5,050 patients were included. Bile leakage rate was higher in the drain group (OR: 2.32; 95% CI 1.18-4.55; p = 0.01) and interventional drains were inserted more frequently in this group (OR: 1.53; 95% CI 1.11-2.10; p = 0.009). Total complications were higher (OR: 1.71; 95% CI 1.45-2.03; p < 0.001) and length of hospital stay was longer (MD: 1.01 days; 95% CI 0.47-1.56 days; p < 0.001) in the drain group. The use of prophylactic drainage showed no beneficial effects after major liver resection; however, the definitions and classifications used to report on postoperative complications and surgical complexity are heterogeneous among the published studies. Further well-designed RCTs with large sample sizes are required to conclusively determine the effects of drainage after major liver resection.


Assuntos
Abdome/cirurgia , Drenagem/métodos , Fígado/cirurgia , Complicações Pós-Operatórias/prevenção & controle , Abdome/patologia , Hepatectomia/efeitos adversos , Humanos , Tempo de Internação , Fígado/patologia , Pâncreas/patologia , Pâncreas/cirurgia , Complicações Pós-Operatórias/patologia , Fatores de Tempo
3.
Langenbecks Arch Surg ; 405(1): 63-69, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32006086

RESUMO

PURPOSE: Live surgical demonstrations are considered an effective educational tool providing a chance for trainees to observe a real-time decision-making process of expert surgeons. No data exists evaluating the impact of live surgical demonstrations on the outcomes of minimally invasive colorectal surgery. This study evaluates perioperative and short-term postoperative outcomes in patients undergoing minimally invasive colorectal surgery in the setting of live surgical demonstrations. METHODS: Patients undergoing minimally invasive colorectal surgery which was performed as live surgical demonstrations (the study group) performed between 2006 and 2018 were reviewed. These patients were case-matched with those undergoing operations in routine practice (the control group). The study and control group were compared for intraoperative and short-term postoperative outcomes. RESULTS: Thirty-nine live surgery cases in the study group were case-matched with its thirty-nine counterparts as the control group. Operating time was longer (200 vs 165 min; p = 0.002) and estimated intraoperative blood loss was higher in the study group (100 vs 55 ml; p = 0.008). Patients in the study group stayed longer in the hospital (6 vs 5 days; p = 0.001). While conversion (n = 4 vs n = 1, p = 0.358) and intraoperative complications (n = 6 vs n = 2, p = 0.2) were more frequent in the study group, these outcomes did not reach statistical significance. Overall complications were higher in the study group (n = 22 vs n = 9, p = 0.003). One patient underwent a reoperation due to postoperative bleeding, and one mortality occurred in the live surgery group. CONCLUSIONS: Live surgical demonstrations in minimally invasive colorectal surgery seem to be associated with increased risk of operative morbidity.


Assuntos
Cirurgia Colorretal/educação , Gastroenteropatias/cirurgia , Procedimentos Cirúrgicos Minimamente Invasivos/educação , Adulto , Idoso , Cirurgia Colorretal/estatística & dados numéricos , Feminino , Humanos , Complicações Intraoperatórias/epidemiologia , Complicações Intraoperatórias/etiologia , Laparoscopia/educação , Laparoscopia/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos/estatística & dados numéricos , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Estudos Retrospectivos , Resultado do Tratamento
4.
Curr Opin Oncol ; 28(2): 145-9, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26730487

RESUMO

PURPOSE OF REVIEW: Cancer is a strong risk factor for venous thromboembolism (VTE). In patients with lung cancer VTE is a significant cause for morbidity and mortality. The purpose of the review is to summarize the epidemiology of thrombotic events, risk factors for VTE and the clinical impact of VTE in patients with lung cancer. RECENT FINDINGS: The rates of VTE in lung cancer patients vary according to different types of investigations, and reach 7 to 13%, including a significant number of unsuspected pulmonary emboli. Risk factors for VTE in patients with lung cancer can be basically divided into three categories: patient, tumor, and treatment related. In addition, a number of biomarkers have been described to be associated with VTE risk (e.g., D-dimer). SUMMARY: Knowledge about the epidemiology, risk factors, and prognostic value of VTE in lung cancer could help to prevent thrombotic complications and improve management of patients with lung cancer.


Assuntos
Neoplasias Pulmonares/patologia , Tromboembolia Venosa/epidemiologia , Trombose Venosa/epidemiologia , Biomarcadores/análise , Humanos , Neoplasias Pulmonares/etiologia , Fatores de Risco , Tromboembolia Venosa/complicações , Trombose Venosa/complicações
5.
Expert Rev Anti Infect Ther ; 13(12): 1457-68, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26414781

RESUMO

Chronic hepatitis B (CHB) is a global health problem, causing liver failure, cirrhosis and hepatocellular carcinoma. CHB treatment aims to prevent liver-related complication. The treatment of CHB infection includes monotherapy with either interferons (IFNs) or nucleos(t)ide (NUC) analogs. IFNs have moderate antiviral effects, and their use is limited by side effects. With the availability of NUCs, IFN-intolerant and decompensated cirrhotic patients began to be treated. Lamivudine and telbivudine, nucleoside analogs, have low genetic barrier to resistance. Adefovir, a nucleotide analog, has moderate potency and potential nephrotoxicity. Entecavir and tenofovir, with their high potency, high genetic barrier to resistance and favorable safety profile are the standard of care in CHB treatment. Long-term use of NUCs with maintained viral suppression results in a decrease in liver-related complications.


Assuntos
Antivirais/administração & dosagem , Hepatite B Crônica/diagnóstico , Hepatite B Crônica/tratamento farmacológico , Adenina/administração & dosagem , Adenina/análogos & derivados , Animais , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/tratamento farmacológico , Carcinoma Hepatocelular/epidemiologia , Guanina/administração & dosagem , Guanina/análogos & derivados , Hepatite B Crônica/epidemiologia , Humanos , Interferons/administração & dosagem , Lamivudina/administração & dosagem , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/epidemiologia , Organofosfonatos/administração & dosagem , Telbivudina , Timidina/administração & dosagem , Timidina/análogos & derivados , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...